| Dr Yusuf Khalid Bhatti, DMD | |
|
12165 Elm St, Princess Anne, MD 21853-1358 | |
| (410) 651-5151 | |
| (410) 651-4256 |
| Full Name | Dr Yusuf Khalid Bhatti |
|---|---|
| Gender | Male |
| Speciality | Dentist - Pediatric Dentistry |
| Location | 12165 Elm St, Princess Anne, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316353204 | NPI | - | NPPES |
| 119591300 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223P0221X | Dentist - Pediatric Dentistry | LL756 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Yusuf Khalid Bhatti, DMD Po Box 1978, Salisbury, MD 21802-1978 Ph: (410) 749-1015 | Dr Yusuf Khalid Bhatti, DMD 12165 Elm St, Princess Anne, MD 21853-1358 Ph: (410) 651-5151 |
News Archive
Celgene Corporation today announced it has received a Paragraph IV Certification Letter advising that Natco Pharma Limited of Hyderabad, India, submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration. The application requests authorization to manufacture and market generic versions of REVLIMID (lenalidomide) 5, 10, 15 and 25 mg capsules in the United States.
The Radiology Business Management Association (RBMA) is the first affiliate organization of the American College of Radiology's Radiology Leadership Institute (RLI). This is the latest step in the development of the RLI — radiology's first professional development and leadership academy — set to launch in July 2012.
For a long time it has been known that the protein TOR - Target of Rapamycin - controls cell growth and is involved in the development of diseases such as cancer and diabetes. Researchers at the University of Basel's Biozentrum together with scientists from ETH Zurich have now examined the structure of mammalian TOR complex 1 (mTORC1) in more detail.
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
› Verified 7 days ago
Stephen Thomas Wagner, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 12137 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 | |
Amar Trivedi, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 281-416-5886 | |
Dr. Robert Mark Schulz, DDS Dentist Medicare: Medicare Enrolled Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 | |
Dr. Celeste Marie Ziara, DDS Dentist Medicare: Medicare Enrolled Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 | |
Dr. Grace Eunheh Kim, DDS Dentist Medicare: Medicare Enrolled Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 | |
Dr. Ariel Karyn Snell, DMD Dentist Medicare: Medicare Enrolled Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 | |
Dr. Reeves Varghese Manikat, DMD Dentist Medicare: Medicare Enrolled Practice Location: 12165 Elm St, Princess Anne, MD 21853 Phone: 410-651-5151 Fax: 410-651-4256 |